Company Overview
Company Type: Public Company
Website: www.hlstherapeutics.com
Number of Employees: 99
Ticker: HLS (TSX)
Year Founded: -


Business Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
85.6
Market Capitalization
157.3
TEV/Total Revenue
3.0x
EBITDA
27.9
Total Enterprise Value
254.9
TEV/EBITDA
9.0x
EBIT
(18.1)
Cash & ST Invst.
28.6
P/Diluted EPS Before Extra
NM
Net Income
(35.7)
Total Debt
128.7
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
310.2
Total Debt/EBITDA
4.5x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.13)
(0.10)
(0.91)
(0.14)
(0.19)
Revenue (mm)
22.26
23.59
88.43
111.30
101.80
EBITDA (mm)
7.35
8.00
29.82
43.12
37.03

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
2.87x
TEV/EBITDA
8.51x
P/BV
1.09x

Non-Periodic Estimates

Recommendation
Outperform (1.75)
Target Price
12.27
Potential Upside
150.46%


Key Professionals
Name
Title
Millian, Craig Stuart
CEO & Director
Hendrickson, Tim 
Chief Financial Officer
Gross, Jason A.
Vice President of Scientific Affairs
Lennox, Ryan C.
Senior VP of Legal, HR & Compliance and Corporate Secretary
Walsh, Brian T.
Senior Vice President of Commercial
Spence, David 
VP & Corporate Controller

Key Board Members
Name
Title
Welborn, John Lee
Independent Chairman of the Board
Millian, Craig Stuart
CEO & Director
Hill, Rodney G.
Independent Director
Beauchamp, Norma 
Independent Director
Brege, Laura A.
Independent Director
Dempsey, Kyle 
Independent Director
Hanna, John 
Independent Director
Roy, Christian 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
10 Carlson Court Suite 701 | Etobicoke, ON | M9W 6L2 | Canada
Phone: 647-495-9000    Fax: 416-213-0045

Current and Pending Investors
Athyrium Capital Management, LP, HealthCor Partners Management LP., Mawer Investment Management Ltd., MVM Partners LLP (Eric Bednarski), NB Alternatives Advisers LLC, OrbiMed Advisors LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.93
Market Cap (mm)
158.0
Open
 5.00
Shares Out. (mm)
32.2
Previous Close
 4.90
Float %
51.5%
Change on Day
0.03
Shares Sold Short (mm)
-
Change % on Day
0.6%
Dividend Yield %
4.1%
Day High/Low
 5.01/ 4.93
Diluted EPS Excl. Extra Items
(1.11)
52 wk High/Low
 11.22/ 4.12
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0063
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
1.26


 
Delayed Quote** | Last Updated on Oct-06-2023 11:56 AM (GMT-5)
TSX:HLS - Common Stock


Index Membership
S&P/TSX SmallCap Index;S&P/TSX Smallcap Index - Health Care (Sector);S&P/TSX Smallcap Index - Pharmaceuticals & Biotechnology (Industry Group);S&P/TSX Smallcap Index - Pharmaceuticals (Industry);S&P/TSX Smallcap Index - Pharmaceuticals (Sub Industry)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Automodular Corporation
As of March 12, 2018, Automodular Corporation was acquired by HLS Therapeutics Inc., in a reverse merger transaction. Automodular Corporation does not have significant operations. Previously, it was engaged in sequencing and sub-assembly of modules for installation in final equipment, which were being assembled by Ford Motor Company in Ontario. The company was formerly known as Algonquin Mercantile Corporation and changed its name to Automodular Corporation in June 2001. Automodular Corporation was founded in 1957 and is based in Pickering, Canada.

United States and Canada
Automotive Parts and Equipment
20.00
24.00
0.00
Automodular Assemblies (Ohio) Inc.

United States and Canada
-
-
-
-
Automodular Assemblies Inc.
Automodular Assemblies Inc. offers sub-assembling services for automotive parts and accessories. It operates three locations in Ontario. The company is based in Whitby, Canada. Automodular Assemblies Inc. operates as a subsidiary of Automodular Corp.

United States and Canada
Automotive Parts and Equipment
-
-
-
HLS Therapeutics (USA), Inc.
HLS Therapeutics (USA), Inc. is a pharmaceuticals company. It is headquartered in Rosemont, Pennsylvania.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-10-2022
-
Buyback
Target
HLS Therapeutics Inc. (TSX:HLS)


-
Nov-04-2021
-
Buyback
Target
HLS Therapeutics Inc. (TSX:HLS)


0.75
Nov-05-2020
-
Buyback
Target
HLS Therapeutics Inc. (TSX:HLS)


0.05
May-7-2020
-
Shelf Registration
Target
HLS Therapeutics Inc. (TSX:HLS)


193.06
May-14-2019
Jun-5-2019
Public Offering
Target
HLS Therapeutics Inc. (TSX:HLS)


32.49
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-12-2023
Company Conference Presentations
HLS Therapeutics Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-12-2023 02:30 PM
Aug-14-2023
Debt Financing Related
HLS Therapeutics Inc. Announces Updates to its Credit Agreement
Aug-10-2023
Earnings Calls
HLS Therapeutics Inc., Q2 2023 Earnings Call, Aug 10, 2023
Aug-10-2023
Buyback Tranche Update
Tranche Update on HLS Therapeutics Inc. (TSX:HLS)'s Equity Buyback Plan announced on November 10, 2022.
Jun-22-2023
Executive/Board Changes - Other
HLS Therapeutics Inc. Announces Board Changes

Competitors
Acerus Pharmaceuticals Corporation, Bausch Health Companies Inc. (NYSE:BHC), Cipher Pharmaceuticals Inc. (TSX:CPH), Knight Therapeutics Inc. (TSX:GUD), Nuvo Pharmaceuticals Inc., PendoPharm Inc., Pharmascience Inc., Purdue Pharma Inc., Searchlight Pharma Inc., Valeo Pharma Inc. (TSX:VPH)

M&A Advisors
Blake, Cassels & Graydon LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Blake, Cassels & Graydon LLP
Private Placement Advisors
Barclays Capital Canada Inc., Bloom Burton & Co. Inc., INTL FCStone Credit Trading LLC
Public Offering Advisors
Blake, Cassels & Graydon LLP, Ernst & Young LLP (Canada)


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:11 AM
HLS
HLS Therapeutics Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 06:16 AM
HLS
ValuEngine - Toronto Quantitative Stock Report for HLS
Reports
5
CFRA Equity Research

Oct 01, 2023 01:15 PM
HLS
HLS Therapeutics Inc.
Reports
9
GlobalData

Sep 13, 2023 02:02 AM
HLS
HLS Therapeutics Inc (HLS.TSE) - Financial Analysis Review
Reports
149
S&P Global Compustat

Sep 07, 2023 04:12 AM
HLS
HLS Therapeutics Inc 2023_09_07
Reports
15
GlobalData

Aug 29, 2023 01:58 AM
HLS
HLS Therapeutics Inc (HLS.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
34
Canaccord Genuity
Armstrong-Whitworth, Tania Rae
Aug 11, 2023 09:35 AM
HLS
Vascepa guidance finally seems achievable
EPS Estimates*
6
Raymond James Ltd.
Sarugaser, Rahul
Aug 10, 2023 03:27 PM
HLS
HLS | 2Q23: Several Headwinds, Some Tailwinds Too
EPS Estimates*
10
Canaccord Genuity
Armstrong-Whitworth, Tania Rae
Aug 10, 2023 06:34 AM
HLS
Q2/23 first look: Okay results marred by Vascepa guidance reduction
Initiation of Coverage*
6
Raymond James Ltd.
Sarugaser, Rahul
Jul 27, 2023 06:50 AM
HLS
HLS | Positive KOL Call on Vascepa: 1 Yr Until Adopt. Inflects | Exclusivity Expires YE27 | PT to $9
EPS Estimates*
12


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Polar Asset Management Partners Inc.

6,409,682

19.88

31.9

May-18-2023


Stadium Capital Management, LLC

5,964,842

18.50

29.6

May-18-2023


Mawer Investment Management Ltd.

3,237,056

10.04

16.1

May-18-2023


Athyrium Capital Management, LP

3,051,782

9.46

15.2

Jun-30-2023


HSBC Global Asset Management (Canada) Limited

280,800

0.87

1.4

Jun-30-2023


Lionguard Capital Management Inc.

142,068

0.44

0.7

Jun-30-2022


Northwest & Ethical Investments L.P.

140,554

0.44

0.7

Mar-31-2023


Welborn Jr., John Lee

97,000

0.30

0.5

Jun-30-2023


ATB Investment Management Inc.

94,020

0.29

0.5

Jun-30-2023


Hendrickson M.B.A., Tim 

67,500

0.21

0.3

Aug-22-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Welborn Jr., John Lee
97,000
97,000
Hendrickson M.B.A., Tim 
67,500
20,000
Picton Mahoney Asset Management
0
12,559
Millian M.B.A., Craig Stuart
5,000
5,000
Hanna, John 
4,000
4,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Athyrium Capital Management, LP
3,051,782
(1,300,000)
Godin M.B.A., Gilbert 
0
(927,000)
Canoe Financial LP
0
(499,001)
Haber Trilix Advisors, LP
0
(425,484)
BMO Asset Management Corp.
0
(418,500)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-07
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
Clozaril, CSAN Pronto, Distribution of MyCare Psychiatry Lab Assays and Monitoring Tests, PERSERIS, Trinomia, Vascepa


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-06-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
26 KB
Aug-14-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
46 KB
Aug-10-2023
Jun-30-2023
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
Interim Financial Statements
302 KB
Aug-10-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
69 KB
Aug-03-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
27 KB
Jul-04-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
Securities Acquisition Filings (Early Warning)
91 KB
Jul-04-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
Securities Acquisition Filings (Early Warning)
179 KB
Jun-22-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
46 KB
Jun-16-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
News Releases
26 KB
Jun-16-2023
-
HLS Therapeutics Inc. (TSX:HLS)
SEDAR
Management Proxy Materials
175 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Hanna, John  (Independent Director)
Aug-25-2023
Common Shares
4,000
18,072
Open Market Acquisition
New
Multiple
Athyrium Capital Management, LP
Jun-30-2023
Common Shares
(1,300,000)
(7,754,576)
Open Market Disposition
(29.87)
Multiple
Welborn Jr., John Lee (Independent Chairman of the Board)
Jun-08-2023
Common Shares
97,000
427,210
Open Market Acquisition
New
Multiple
Millian M.B.A., Craig Stuart (CEO & Director)
May-19-2023
Common Shares
2,000
9,301
Open Market Acquisition
66.67
Multiple
Hendrickson M.B.A., Tim  (Chief Financial Officer)
May-19-2023
Common Shares
10,000
45,573
Open Market Acquisition
17.39
Multiple
-
May-19-2023
Common Shares
2,800
12,756
Open Market Acquisition
-
Exchange Announcement
-
May-19-2023
Common Shares
3,900
17,807
Open Market Acquisition
-
Exchange Announcement
-
May-19-2023
Common Shares
800
3,620
Open Market Acquisition
-
Exchange Announcement
-
May-19-2023
Common Shares
2,500
11,390
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Welborn, John Lee
Independent Chairman of the Board
647-495-9000 
416-213-0045
jwelborn@stadiumcapital.com
Millian, Craig Stuart
CEO & Director
647-495-9000 
416-213-0045

Hill, Rodney G.
Independent Director
647-495-9000 
416-213-0045

Beauchamp, Norma 
Independent Director
647-495-9000 
416-213-0045

Brege, Laura A.
Independent Director
647-495-9000 
416-213-0045
lbrege@xdx.com
Dempsey, Kyle 
Independent Director
647-495-9000 
416-213-0045
kd@mvm.com
Hanna, John 
Independent Director
647-495-9000 
416-213-0045

Roy, Christian 
Independent Director
647-495-9000 
416-213-0045

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Millian, Craig Stuart
CEO & Director
647-495-9000 
416-213-0045

Hendrickson, Tim 
Chief Financial Officer
647-495-9000 
416-213-0045

Gross, Jason A.
Vice President of Scientific Affairs
647-495-9000 
416-213-0045

Lennox, Ryan C.
Senior VP of Legal, HR & Compliance and Corporate Secretary
647-495-9000 
416-213-0045
r.lennox@hlstherapeutics.com
Walsh, Brian T.
Senior Vice President of Commercial
647-495-9000 
416-213-0045

Spence, David 
VP & Corporate Controller
647-495-9000 
416-213-0045

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
